A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Trial Parameters
Brief Summary
There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial. 2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination therapy or monotherapy in the treatment of HCC compared to the combination of Sintilimab and Bevacizumab biosimilar.
Eligibility Criteria
Inclusion Criteria: 1. Be able and willing to provide written informed consent. 2. Have a life expectancy of at least 3 months. 3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. HCC confirmed by histology/cytology or confirmed by the American Society for the Study of Hepatology (AASLD) clinical diagnostic criteria for hepatocellular carcinoma in patients with cirrhosis. 5. Phase Ib: 1. Barcelona Clinical Liver Cancer (BCLC) stage B or C. 2. Has failed standard treatment and has received no more than two lines of anti-tumor treatment in the past; Phase II: 1. The BCLC staging is stage C, which is not suitable for curative and local treatment, or for stage B that cannot be cured after curative and/or local treatment. 2. Subjects who have not received any systematic anti-tumor treatment for HCC in the past. 6. According to RECIST v1.1, there is at least one untreatable measurable lesion, or a measurable lesion with clear imaging progression after local